ProPhase Labs, Inc.
PRPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.01 | -0.00 | -0.00 |
| FCF Yield | -113.17% | -5.19% | -43.83% | 15.48% |
| EV / EBITDA | -5.52 | -6.72 | -8.53 | -2.75 |
| Quality | ||||
| ROIC | -28.43% | -21.48% | -11.50% | -74.00% |
| Gross Margin | -13.93% | 58.86% | 36.76% | -37.20% |
| Cash Conversion Ratio | 3.15 | 0.06 | 0.72 | -0.07 |
| Growth | ||||
| Revenue 3-Year CAGR | -74.20% | -65.10% | -63.56% | -61.92% |
| Free Cash Flow Growth | -2,450.12% | 75.04% | -240.93% | 157.04% |
| Safety | ||||
| Net Debt / EBITDA | -1.53 | -2.16 | -5.49 | -1.67 |
| Interest Coverage | 3.08 | -6.63 | -6.80 | -14.09 |
| Efficiency | ||||
| Inventory Turnover | 3.78 | 0.62 | 0.79 | -2.98 |
| Cash Conversion Cycle | -911.41 | -1,041.91 | 59.32 | -394.68 |